Clinical Trial Update: Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes [Phase 1]

View source ↗

Summary

Phase I trial update assessing the immunogenicity of three GTU® MultiHIV DNA immunisations delivered via intramuscular, intradermal, and transcutaneous routes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• GTU® MultiHIV DNA Immunisations

Snippet

Sponsor: Imperial College London | Conditions: HIV | Phase 1 | Status: UNKNOWN